Treatment with HSPC-NK cell infusions and DAC improves control of AML in vivo. (A) Experimental design: THP-1–bearing mice received 1 or 2 cycles of DAC (1.25 mg/m2), with or without HSPC-NK cells, which were infused on the first day from each cycle. Survival of HSPC-NK cells in vivo was supported by ALT-803 (an IL-15 superagonist complex), which was given subcutaneously every 3 to 4 days until day 35 (0.2 mg/kg per injection). Groups that were not treated with NK cells were also given ALT-803 as a control. (B) Impact of DAC on tumor load progression. Median tumor load from untreated mice and mice treated with 1 or 2 cycles of DAC is shown. (C) Impact of HSPC-NK cell infusions on tumor load progression in mice cotreated with 2 cycles of DAC. Data are shown as mean ± SD and were analyzed with 2-way ANOVA. One mouse in each DAC × 2 and DAC+NK × 2 group died at day 17 and day 15, respectively, likely due to DAC-related toxicities (weight loss >20% after second treatment cycle). These mice were excluded from the complete data set shown in this figure.
